Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 166 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: DM Clear all
Terminated Phase 2 Interventional Results available

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

NCT00451321
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Otelixizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 28, 2026, 7:39 AM EDT
Completed Phase 2 Interventional

Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

NCT05479981
View directory record Official record
Conditions
DM1, Muscular Dystrophies, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonic Disorders, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, Neurodegenerative Diseases
Interventions
Placebo, AOC 1001
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 28, 2026, 7:39 AM EDT
Completed Not applicable Interventional

Comprehensive Intervention to Evaluate Outcomes AND Cost in Hospitalized Surgical Patients With Diabetes Mellitus (DM)

NCT02065050
View directory record Official record
Conditions
Diabetes
Interventions
team-based care
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 28, 2026, 7:39 AM EDT
Completed Phase 2 Interventional Results available

Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)

NCT00106184
View directory record Official record
Conditions
Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis
Interventions
Rituximab, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
5 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 28, 2026, 7:39 AM EDT
Enrolling by invitation Phase 2 Interventional

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

NCT06926621
View directory record Official record
Conditions
Myotonic Dystrophy Type 1 (DM1)
Interventions
VX-670
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
St Louis, Missouri • Winston-Salem, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 7:39 AM EDT
Completed Not applicable Interventional Results available

Targeted Adherence Intervention to Reach Glycemic Control With Insulin Therapy for Patients With Diabetes

NCT02846779
View directory record Official record
Conditions
Diabetes
Interventions
Low intensity, Moderate intensity, High intensity
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 28, 2026, 7:39 AM EDT
Completed No phase listed Observational

Delphinus SoftVue™ ROC Reader Study

NCT03972605
View directory record Official record
Conditions
Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
Interventions
Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 28, 2026, 7:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detection of Human Beta Cell Death in Type 1 Diabetes Mellitus (T1DM) by Methylation Specific Polymerase Chain Reaction (PCR)

NCT01176253
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood draw
Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
2
States / cities
Duarte, California • Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 28, 2026, 7:39 AM EDT
Completed Not applicable Interventional Results available

OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy

NCT01182493
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Pump (Medtronic Minimed Paradigm® VEO)
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Albany, New York • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 28, 2026, 7:39 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

NCT03095066
View directory record Official record
Conditions
Neurobehavioral Disinhibition
Interventions
Placebo, AVP-786-28, AVP-786-42.63
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
54
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 28, 2026, 7:39 AM EDT
Terminated Not applicable Interventional

Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)

NCT00743756
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
home-delivered meals, diabetes education for 12 months
Dietary Supplement · Behavioral
Lead sponsor
Emory University
Other
Eligibility
65 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 28, 2026, 7:39 AM EDT
Enrolling by invitation No phase listed Observational

BETA - Pilot Study

NCT07192861
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Not listed
Lead sponsor
4YouandMe
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 28, 2026, 7:39 AM EDT
Terminated Phase 3 Interventional Results available

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT02446132
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
171
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 28, 2026, 7:39 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

NCT05669014
View directory record Official record
Conditions
Idiopathic Inflammatory Myositis
Interventions
Daxdilimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 28, 2026, 7:39 AM EDT
Recruiting Phase 2 Interventional

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
5% TolaSure Topical Gel, Topical Placebo Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 28, 2026, 7:39 AM EDT
Completed Not applicable Interventional

Iron Depletion Therapy for Type 2 DM and NAFLD

NCT00230087
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus
Interventions
blood donation
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 28, 2026, 7:39 AM EDT
Completed Not applicable Interventional

Wearable Devices on Health Promotion in Diabetes

NCT07144774
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Fitbit wrist-worn Inspire 2® activity tracker (Fitbit Inc., San Francisco, CA, USA)
Device
Lead sponsor
Pacific University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Hillsboro, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 28, 2026, 7:39 AM EDT
Not listed Not applicable Interventional

Continuous Glucose Monitoring for Personal Protective Equipment Evaluation

NCT05478070
View directory record Official record
Conditions
Diabetes Mellitus (DM)
Interventions
Dexcom G6
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 28, 2026, 7:39 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Combining Shockwave Therapy and Platelet Rich Plasma to Treat Erectile Dysfunction in Diabetic Men (COCKTAIL-DM)

NCT05525572
View directory record Official record
Conditions
Erectile Dysfunction With Diabetes Mellitus
Interventions
Shockwave Therapy (SWT), Autologous Platelet-Rich Plasma (PRP)
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 28, 2026, 7:39 AM EDT
Completed Not applicable Interventional

Evaluation of the Impact of a Food is Medicine Program on Diabetes-related Health Outcomes for People With Type 2 Diabetes in a Low Income Community-based Setting Compared to Usual Care

NCT07529184
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Food is medicine
Dietary Supplement
Lead sponsor
Public Health Institute Center for Wellness and Nutrition
Other
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Stockton, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 28, 2026, 7:39 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

NCT06185764
View directory record Official record
Conditions
Myotonic Dystrophy Type 1 (DM1)
Interventions
VX-670, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
San Carlos, California • Gainesville, Florida • Fairway, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 28, 2026, 7:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Maternal Adipose Tissue and Placental Dysfunction Programs the Fetus for Type 2 Diabetes (PlacentA-DM)

NCT02211651
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Not listed
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 28, 2026, 7:39 AM EDT
Terminated Not applicable Interventional Results available

Effect of Raised CBF During CEA on Cognition in DM Patients

NCT00597545
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Artery Stenosis, Diabetes, Cognitive Dysfunction
Interventions
Carotid endarterectomy, Shunt
Procedure · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 28, 2026, 7:39 AM EDT
Recruiting Phase 3 Interventional

RCT Glargine vs NPH for Treatment of DM in Pregnancy

NCT06619301
View directory record Official record
Conditions
Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
Interventions
Insulin glargine, insulin NPH
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 28, 2026, 7:39 AM EDT